Columbia Laboratories’ revenues boost 11 percent to $32.5 million in 2014 Columbia Laboratories, Inc http://cialisprix.net/foire-aux-questions.html . , today announced economic results for the three – and twelve-month intervals ended December 31, 2014. During this transitional yr we restarted our medication development activities, significantly strengthened our management team, and generated a substantial amount of cash,’ mentioned Frank Condella, CEO. We look forward to initiating the Stage II study of COL-1077, a lidocaine bioadhesive gel designed as an acute use anesthetic for minimally invasive gynecological procedures, in the second quarter of 2015.
cialis 20 mg
Columbia Laboratories amends permit, supply agreement with Merck Serono for CRINONE Columbia Laboratories, Inc. provides amended its license and supply agreement with Merck Serono, a division of Merck KGaA . The early renewal of this contract through 2020 provides long-term stability for Columbia and surety of source for Merck Serono as they look to continue their expense in CRINONE globally. We anticipate continued positive cash flow from our core business as Merck Serono builds further product sales momentum for CRINONE.